Accurin

Accurin. It is an investigational nanoparticle drug delivery system designed to improve the therapeutic index of potent chemotherapy agents by targeting the tumor microenvironment. Developed by BIND Therapeutics, the platform utilizes polymeric nanoparticles to encapsulate drugs, aiming to enhance drug efficacy while reducing systemic toxicity. This targeted approach represents a significant advancement in the field of oncology and nanomedicine.

Overview

The Accurin platform is built upon core-shell nanoparticle technology, where a biodegradable polymer forms the particle matrix. These particles are engineered to circulate in the bloodstream for extended periods, leveraging the enhanced permeability and retention effect common in many solid tumors. The technology originated from foundational research at the Massachusetts Institute of Technology and the Brigham and Women's Hospital. Key figures in its development include Robert Langer and Omid Farokhzad, whose work on targeted nanoparticles paved the way for its clinical translation.

Mechanism of action

Accurins function by encapsulating a chemotherapeutic payload, such as docetaxel or SN-38, within a poly(lactic-co-glycolic acid) shell. The nanoparticles are surface-functionalized with polyethylene glycol to evade the reticuloendothelial system and prolong circulation half-life. Upon extravasation into tumor tissue, the particles are designed to release their cargo in response to specific conditions within the tumor microenvironment, such as lowered pH or the presence of certain enzymes. This controlled release mechanism aims to achieve high intratumoral drug concentration while minimizing exposure to healthy tissues like the bone marrow and gastrointestinal tract.

Clinical applications

The primary clinical focus for Accurin technology has been in treating advanced solid tumors. BIND Therapeutics initiated clinical trials, including a Phase I study for BIND-014, an Accurin containing docetaxel, in patients with non-small cell lung cancer, prostate cancer, and other carcinomas. Preliminary research suggested potential activity in KRAS-mutant tumors, which are often resistant to conventional therapies. Further development was explored for delivering camptothecin analogs to treat colorectal cancer and pancreatic cancer.

Development and technology

The development of the Accurin platform involved extensive preclinical studies demonstrating improved pharmacokinetics and biodistribution in animal models. BIND Therapeutics, founded in 2007, advanced the technology through partnerships with major pharmaceutical companies like Pfizer and AstraZeneca. Manufacturing utilizes a proprietary nanoprecipitation process to ensure precise particle size and drug loading. The company filed numerous patents covering the polymer composition, surface modification, and ligand targeting strategies, although financial challenges later led to the company's bankruptcy and acquisition of its assets by Pfizer.

Comparison to conventional therapies

Compared to conventional intravenous chemotherapy, Accurins aim to provide a superior safety profile by reducing neutropenia, neuropathy, and other dose-limiting toxicities. Unlike traditional nanoparticle formulations like Abraxane, which is an albumin-bound particle, Accurins employ active molecular targeting via surface ligands. While liposomal systems such as Doxil also improve drug delivery, the polymeric nanoparticle core of Accurins allows for greater control over drug release kinetics. The technology faces similar challenges as other nanomedicines, including scale-up complexity and demonstrating clear overall survival benefits in late-stage clinical trials against established standards of care like Gemzar or Taxotere.

Category:Experimental drugs Category:Nanomedicine Category:Drug delivery systems